Watch · 63/100 · medium confidence

Doximity, Inc. (DOCS) — Council Assessment

🟡 WATCH · Score 63/100 · medium confidence

Exceptional capital-light physician network trading at a reasonable 11.7x FCF, but decelerating growth, a KPI-misstatement settlement, and AI-cost/margin pressure keep it a Watch, not a Buy.

As of 2026-06-28. 18 lenses weighed in, 0 abstained. Sources: 6 filings, 15 news, 15 discussion, 1 earnings_call.

360 narrative — news & sentiment digest

DOXIMITY, INC. (DOCS) — INVESTMENT BRIEFING

Management Commentary (Earnings Call)

Q2 FY2026 Results (ended Sept 30, 2025)

Revenue: $169M (+23% YoY), beat high end of guidance by 7%
Adjusted EBITDA: $101M (60% margin), +32% YoY, 15% above guidance high end
Free cash flow: $91.6M (+37% YoY)
Net revenue retention (NRR): 118% (trailing 12-month)
Customer cohort: 121 customers at $500K+ ARR (16% growth YoY), representing 84% of total revenue
Gross margin: 92% (flat YoY)

AI & Product Momentum

AI tool quarterly active users up 50% QoQ; new scribe users nearly tripled Q1-to-Q2
Pathway acquisition (announced ~7 weeks prior, fully integrated): integrated drug reference with peer-reviewed answers in <1 second; partnership with Research Solutions enabling access to 2,000+ medical journals (full PDF, no paywalls)
News feed: all-time record prescribers; "Ask Docs GPT" feature launched
Workflow tools: 650K unique prescribers in Q2 (all-time high); telehealth (Dialer) handling 300K+ voice/video visits/weekday
AI-optimized integrated programs: grew from <5% of bookings a year ago to 40% of Q2 bookings

Guidance & Strategic Shift

FY2026 updated outlook: Revenue $640–646M (13% growth midpoint), EBITDA $351–357M (55% margin midpoint)
Q3 FY2026: Revenue $180–181M (7% growth), EBITDA $103–104M (57% margin)
Key insight: Integrated AI programs are smoothing upsell timing. Historically, clients bunched upsell spending in Q3/Q4 after reviewing annual results; now they evaluate results sooner and spend more evenly through the year. This led to stronger-than-typical Q2 and implies lower-than-historical step-up into Q3. Management frames this as positive long-term (better ROI visibility, customer stickiness, predictability).
Pharma portal & SMB: Agency partners driving ~100% YoY growth in SMB bookings via portal insights; portal users up 3x YoY.

Hedges & Caution

Policy uncertainty: Management acknowledges uncertainty around 2026 calendar budgets (being finalized over next ~2 months). D2C advertising under pressure (Trump admin warning letters; some brands tweaking strategy). Impact on HCP/pharma budgets still unclear—potential tailwinds and headwinds both in play.
Q4 guidance implies caution: Implied Q4 growth lower than prior years, reflecting "measured approach to revenue we have yet to book."
AI investment ramp: Expecting increased R&D/infrastructure costs in back half FY2026 to build and power AI solutions; still targeting 55%+ adjusted EBITDA margins.

Tone: Confident in product/market fit and platform stickiness (118% NRR, client engagement high), but acknowledging near-term macro/policy headwinds. Management emphasizes long-term opportunity in AI and workflow consolidation.

Recent Developments

Pathway acquisition (announced Aug 2025, integrated by Nov 2025): 6-person team, medical knowledge corpus; now live in Docs GPT across web and mobile.
Research Solutions partnership: Access to 2,000+ peer-reviewed medical journals; integrated into Docs GPT.
Q2 FY2026 beat: Revenue, EBITDA, and free cash flow all exceeded guidance; strong growth in integrated programs and SMB via agency partners.
Litigation settlement: $31M investor settlement (June 2026 news items) for claims covering June 2024–Aug 2023 period; alleged misstatement of user engagement and KPIs. Deadline to file claim: July 16, 2026.

Bull Narrative

Product & Market Position

Defensible moat: 118% NRR, 84% revenue from 121 large customers ($500K+ ARR), and strong physician network engagement (1M+ news feed users) create sticky, expanding relationships.
AI is real, differentiated: Integrated drug reference + 2K+ journal access (via Research Solutions) vs. competitors' limitations. Blind physician preference tests show DOCS winning "decisively" on answer quality/depth (per CEO).
Scribe adoption explosive: 3x user growth Q1–Q2; clinician testimonials ("out of office by 5:15 PM") highlight real time-savings value.
Integrated programs = margin accretion + predictability: 40% of bookings now AI-optimized; smoother upsell cycle, better client ROI visibility, and improved business predictability vs. lumpy Q4 flushes. This positions DOCS for steadier growth and margin expansion.

Financial Health

60% adjusted EBITDA margin, 92% gross margin, strong FCF generation ($91.6M Q2).
Share repurchase program active ($21.9M in Q2; $280M remaining authorization).
Cash position solid: $878M on balance sheet.

Growth Runway

AI QAU growth (50% QoQ), scribe, telehealth (300K+ daily calls), and health system AI adoption (top-20 hospitals already signed) suggest early-stage monetization of workflow platform.
CEO ("taking it all the way") and VP Investor Relations signal long-term commitment to AI expansion; ~100 people in AI dev shop.

Bear Narrative

Macro Headwinds & Guidance Softness

Policy uncertainty: D2C advertising scrutiny (Trump admin); 2026 calendar budgets still being finalized. Management explicitly cautioning on "measured approach" to unbooked revenue (Q4 implied growth lower than historical).
Growth deceleration: FY2026 guidance at 13% midpoint growth, down from 23% in Q2. Q3 guidance only 7% growth. While management blames "timing" of AI program launches, it still signals slower absolute growth ahead.
Upsell cycle timing shift as double-edged sword: Pulling forward Q3/Q4 bookings into H1 may create tougher comparisons and revenue lumpiness. "Smoother" for clients ≠ necessarily higher total spend.

Profitability & AI Costs

Margin pressure from AI: Management flagging rising costs for AI infrastructure/development in back half; offsetting some EBITDA upside. While still targeting 55%+ margins, this is below current 60% and implies margin compression.
Customer concentration: 84% of revenue from 121 large customers. Losing a few could be material.

Litigation & Reputational Risk

$31M settlement: Underlying suit alleges misstatement of user engagement and KPIs (covered June 2024–Aug 2023). Suggests prior credibility issues with investors and potential past over-claiming of platform metrics.
Risk factors: 10K filed May 2026 shows risk-factor language 43% above peer average, citing AI operational/legal/regulatory risks, third-party model dependencies, management turnover, and litigation exposure.

Market Skepticism

Stock down 75% from highs (per TIKR headline, March 2026).
Analyst divergence: JPMorgan reiterates Neutral with $26 target (June 2026); DirectorsTalk reports analyst consensus ~26% upside (May 2026), but context suggests price significantly below consensus at time of reporting.
Retail chatter mixed: Some bullish sentiment, but also shorts/put trades and settlement claim reminders.

Retail Sentiment

Mixed-to-cautious overall, with conviction low:

Bullish posts (May–June 2026) focus on strong product (AI, scribe), profitability, and upside potential (26–79% implied returns in options chatter).
Bearish/skeptical sentiment centers on settlement liability, stock decline from highs, litigation risk, and management credibility concerns (implicit in multiple settlement reminders).
Uncertainty: Retail traders asking "is it a good buy?" and "am I an idiot?" suggests low conviction and fear of further downside.
Limited volume: Most posts are settlement claims, analyst snippets, or light speculation—not sustained bull/bear thesis.

Caveats

Timing of call: Earnings call dated Nov 17, 2025 (labeling says "Nov 6, 2025" in disclaimers), but news and chatter extends through June 2026. May create narrative misalignments if business deteriorated materially post-call.
Settlement claim spam: Multiple June 2026 posts are settlement deadline reminders (July 16, 2026 cutoff); these crowd out substantive discussion and may distort retail sentiment perception.
Pathway valuation opaque: No disclosed purchase price for Pathway; CEO says it was "reasonable" and paid for "best people." Hard to assess overpayment risk or ROI timeline.
"Policy uncertainty" vague: Management doesn't quantify D2C budget risk or model downside scenarios; relies on "tailwinds and headwinds" language. Implies low visibility into Q4 and FY2027.
AI adoption metrics early: Scribe users tripled, but absolute base unclear; QAU growth is high but from potentially small base. Revenue contribution from AI not yet material (management treating as investment phase).
Analyst coverage thin: Only JPMorgan and DirectorsTalk snippets in material; broader Street coverage not visible.
Stock price context: June 2026 headlines reference stock at all-time lows (~$20–31 range); June 10 discussion cites $20.69 with $31M market-cap context, but absolute valuation metrics (P/E, EV/FCF) not provided in material.

Summary

DOCS is a high-margin, capital-efficient SaaS business with strong physician engagement (118% NRR) and credible AI product momentum. The integrated AI program shift is strategically sound and improving customer economics. However, near-term headwinds (policy uncertainty, softening guidance, expected margin compression from AI R&D) and longer-term questions (can AI actually drive new revenue streams, or just optimize existing pharma spend?) leave the investment case on rocky footing. The $31M settlement, management turnover risk flagged in 10K, and stock's decline from highs suggest prior credibility damage and investor skepticism. For the investment council: DOCS merits conviction on the product/platform thesis but carries meaningful execution and macro risk in the next 12–24 months.

Bull case

DOCS is a genuinely high-quality franchise: 92% gross margins, 50.6% FCF margin ($326M on $645M revenue), 118% NRR, ROIC of 17.3% versus a 10.7% WACC, and a fortress balance sheet with effectively zero debt and ~$879M liquidity. The quality lenses (Terry Smith 76, Munger 74, Mauboussin 74) and both referees (Valuation 74, Forensic Short 72) converge that the price embeds near-zero growth pessimism. The Damodaran-style DCF puts base value at $33.26 (bear $27.31), implying 31-59% upside, and the forensic test is unusually clean — FCF exceeds net income, no accrual games. AI-integrated programs jumping from <5% to 40% of bookings and 118% NRR suggest the moat is deepening, not eroding.

Bear case

The tape and the trajectory disagree with the intrinsic-value story. The stock is down ~75% from highs sitting near all-time lows; Q3 growth is guided at only 7% versus 23% in Q2, net income actually fell 12% YoY in FY2025, and management is guiding EBITDA margins down from 60% toward 55% as AI infrastructure costs ramp. A $31M securities settlement alleging misstatement of the very user-engagement KPIs that justify pharma willingness-to-pay is a real integrity scar, compounded by 10-K risk language 43% above peer average and 84% revenue concentration in 121 clients. The DCF is 71.9% terminal value; on an earnings-power (EPV) basis Greenwald pegs fair value near or below the current price, meaning the entire premium is a growth bet in a business whose core pharma-matching revenue faces AI/first-party-data disintermediation risk over 5-10 years.

Dissent — where the council disagrees

The council is genuinely split. Druckenmiller (AVOID 32) and Schloss (AVOID 28) are the sharpest dissenters: Druckenmiller sees a falling knife with a negative second derivative, no catalyst, and no invalidation point — 'never fight the tape'; Schloss sees 3.9x book with no tangible asset floor. Their view matters because the four PASS votes all rest on the DCF's $33.26, which is 72% terminal value and assumes 12% FCF growth that Q3's 7% guide directly contradicts. Greenwald (WATCH 58) underscores this: on EPV the stock is NOT cheap once you strip out the growth bet, so the bulls are paying for growth in a business that is decelerating. Dalio flags single-regime dependence on discretionary US pharma promo budgets. The tension: the price only 'requires excessive pessimism' if you trust the growth assumption — and the same settlement that damaged credibility was about the metrics underpinning that growth.

Key risks

Growth deceleration: Q3 guided to 7% vs 23% in Q2; net income already fell 12% YoY in FY2025
Management credibility: $31M securities settlement over alleged misstatement of user-engagement KPIs, the very metrics driving pharma willingness-to-pay
Customer concentration: 84% of revenue from 121 clients; loss of 10-15 accounts would be structurally material
Margin compression: AI infrastructure ramp guiding EBITDA from 60% toward 55%, with monetization timeline unproven
Valuation fragility: 71.9% of DCF value is terminal; EPV analysis suggests fair value near/below current price absent growth
Disruption risk: core pharma-matching revenue exposed to first-party pharma data + hyperscaler/Epic-Nuance workflow competition over 5-10 years

Catalysts

Re-acceleration of revenue growth back toward mid-teens on AI-integrated program monetization
NRR holding at 115%+ and AI-optimized bookings sustaining 20%+ growth (disproves disruption thesis)
Continued accretive buybacks at depressed prices (net share count declining after SBC)
Resolution of pharma D2C policy/budget uncertainty with a demand tailwind
Evidence AI infrastructure costs are being expensed (not capitalized) and margins stabilize above 55%

DCF valuation (finance-expert model)

two-stage DCF, Gordon terminal value, CAPM-weighted WACC.

Intrinsic value: $33.26/share vs price $20.88 → +59% (bear $27.31 · base $33.26 · bull $38.06).

Step	Value
Base free cash flow	$326M
FCF growth (yrs 1-5)	12.0% (revenue CAGR)
WACC (β 1.28)	10.7%
Terminal growth	2.5%
PV of explicit FCF	$1.7B
PV of terminal (residual) value	$4.3B (72% of EV)
Enterprise value	$6.0B
less Net debt	$-65M
= Equity value	$6.1B
/ Shares (183M) = intrinsic/share	$33.26

Short-sell evaluation

🚫 AVOID SHORTING

Despite decelerating growth, AI margin pressure, and a genuine credibility scar, DOCS is a poor short. The forensic short-seller himself scored it a PASS (72) because the accounting is cleaner than clean — FCF ($326M) exceeds net income ($196M), capex is ~zero, there is no debt or refinancing risk, and $879M liquidity plus active buybacks. It trades at only 11.7x FCF and 19.5x P/E — already down ~75% from highs and near 52-week lows — so much of the bear case is priced in, and the DCF (even the bear case) sits above the current price. Shorting a fortress-balance-sheet, 50%-FCF-margin franchise trading below intrinsic value into a downtrend invites squeeze and mean-reversion risk with unlimited downside. This is a Watch on the long side, not a short.

Pros (the short could work)

Growth decelerating hard (Q3 7% vs Q2 23%; net income -12% YoY) with negative second derivative
AI infrastructure costs compressing EBITDA margins from 60% toward 55% with no proven monetization offset
$31M settlement over misstated engagement KPIs plus 10-K risk language 43% above peer — governance/credibility overhang
84% revenue concentration and single-regime dependence on discretionary US pharma promo budgets create cliff risk
72% of DCF value is terminal; on EPV basis the stock is not cheap once growth is stripped out

Cons (what kills the short)

Pristine forensics: FCF far exceeds net income, no accrual stuffing — the forensic short-seller scored PASS not short
Fortress balance sheet: zero debt, ~$879M liquidity, 6.6x current ratio — no financing-distress catalyst
Already down ~75% from highs and near 52-week lows at 11.7x FCF — much of the bear case is priced in
DCF bear case ($27.31) is above current price; asymmetry favors longs not shorts
Active buybacks ($280M remaining), 118% NRR, and durable network-effect moat support downside
Unlimited-loss asymmetry on shorting a profitable, cash-rich franchise if AI monetization re-rates it up

Council scorecard

Lens	School	Stance	Score	Conf
Terry Smith (Fundsmith)	quality	🟢 pass	76	medium
Valuation Referee (Damodaran-style)	referee	🟢 pass	74	medium
Charlie Munger	quality	🟢 pass	74	medium
Michael Mauboussin	quality	🟢 pass	74	medium
Forensic Short-Seller (Chanos/Einhorn-style)	referee	🟢 pass	72	medium
Chuck Akre	quality	🟡 watch	62	medium
Warren Buffett	quality	🟡 watch	62	medium
Philip Fisher	growth	🟡 watch	62	medium
Joel Greenblatt	value	🟡 watch	58	medium
Bruce Greenwald	value	🟡 watch	58	medium
Peter Lynch	growth	🟡 watch	58	medium
AI & Disruption Referee (Christensen-style)	referee	🟡 watch	58	medium
Howard Marks	risk	🟡 watch	55	medium
Ray Dalio	risk	🟡 watch	52	medium
Benjamin Graham	value	🟡 watch	52	medium
Seth Klarman	value	🟡 watch	52	medium
Stanley Druckenmiller	risk	🔴 avoid	32	high
Walter Schloss	value	🔴 avoid	28	high

Member reasoning

Terry Smith (Fundsmith) — 🟢 pass · 76/100 · medium confidence

Doximity passes the Fundsmith quality screen on most of the key criteria, though with some genuine concerns that prevent a high-conviction score. On the fundamentals that matter most to me: the business is genuinely high-quality. Gross margins of 92% are exceptional and signal real pricing power — you do not achieve those margins without meaningful switching costs and network effects (1M+ physicians, 118% NRR). Operating margins of 33% GAAP (and reportedly 55%+ adjusted EBITDA) are durable and expanding from a profitable base. Free cash flow conversion is outstanding — FCF of $326M against net income of $196M means cash conversion well above 100%, driven by the asset-light model (capex is effectively zero per the filings). ROIC of 17% and ROE of 20% are solid, though I would prefer to see pre-tax ROCE consistently above 25% to feel truly comfortable. The balance sheet is fortress-like: total liabilities of $178M against assets of $1.16B, no meaningful debt, and a current ratio of 6.6x. This is a self-funding, zero-capex business that compounds internally — exactly what I look for. On valuation: at $20.88 with FCF of $326M and 183M shares, the FCF yield is roughly 8.5% (price-to-FCF of 11.7x), which is genuinely reasonable for a business of this quality. The DCF intrinsic value of $33.26/share implies nearly 60% upside on the base case, with even the bear scenario ($27.31) offering margin of safety above current price. P/E of 19.5x on a 50%+ FCF margin business with 15% revenue CAGR is not expensive. However, several concerns temper my enthusiasm. First, the $31M securities settlement alleging misstatement of user engagement metrics is troubling — I do not like management credibility questions, and the 10K risk factor language running 43% above peer average is a yellow flag. Second, revenue concentration (84% from 121 customers, all pharma/healthcare marketers) creates customer concentration risk I would prefer not to own. Third, the AI-driven margin compression flagged for H2 FY2026 is worth watching — Fundsmith businesses should expand or hold margins, not compress them due to infrastructure costs. Fourth, the Pathway acquisition, while small, represents the beginning of an M&A habit I would monitor carefully. Fifth, the growth deceleration from 23% to guided 7% in Q3 raises questions about whether the 12% FCF growth assumed in the DCF is achievable. The physician network moat is real, the recurring revenue from pharma marketing is genuinely sticky, and the cash generation is exceptional. This is a quality business at a fair price, not a cheap business at a great price — which is exactly the Fundsmith sweet spot when quality is high enough.

Key points

92% gross margin and 50%+ FCF margin demonstrate genuine pricing power and exceptional asset-light economics — capex is effectively zero
118% net revenue retention confirms sticky, expanding customer relationships; classic network-effect moat with 1M+ physicians
FCF of $326M dramatically exceeds net income of $196M, confirming pristine cash conversion with no accruals game
Zero net debt, current ratio of 6.6x, $879M+ liquidity — balance sheet is a fortress enabling self-funded growth and buybacks
Price-to-FCF of 11.7x is genuinely attractive for a business of this quality; DCF base case of $33.26 implies 59% upside with bear case still above current price
Revenue CAGR of 15.5% over 3 years with 33% operating margins demonstrates the compounding engine is intact

Red flags

$31M securities settlement alleging misstatement of user engagement KPIs (2021–2023) raises management credibility concerns — Fundsmith demands trustworthy stewards
Revenue concentration: 84% from just 121 customers creates material risk if pharma marketing budgets shift or key accounts churn
AI infrastructure investment flagged to compress margins in H2 FY2026 — margin expansion must resume or the moat narrative weakens
Risk factor language in 10K running 43% above peer average, flagging AI regulatory/legal risks, management turnover, and third-party model dependencies
Growth deceleration from 23% (Q2 FY2026) to guided 7% (Q3 FY2026) questions the sustainability of double-digit compounding assumed in the DCF
Pathway acquisition, while small, begins an M&A track record to monitor — serial acquisitions would be a Fundsmith disqualifier

Valuation Referee (Damodaran-style) — 🟢 pass · 74/100 · medium confidence

The two-stage DCF yields an intrinsic value of $33.26/share against a current price of $20.88, implying ~59% upside. Even the bear-case sensitivity ($27.31) sits 31% above the current price, meaning the stock offers a margin of safety that survives conservative-but-fair assumptions. The DCF uses a 10.7% WACC (beta 1.28, reasonable for a capital-light SaaS in healthcare), 12% FCF growth (anchored to the 15.45% 3-year revenue CAGR — slightly conservative given the actual CAGR), and 2.5% terminal growth (below long-run nominal GDP, appropriate for a mature platform). The terminal value is 71.9% of EV — elevated but not unreasonable for a recurring-revenue, high-margin SaaS franchise. The underlying economics are genuinely strong: 50.6% FCF margin (FY2025 $326M FCF on $645M revenue), zero reported capex (asset-light model), 33.3% operating margin, 92% gross margin, and ROIC of 17.3% well above the 10.7% WACC — growth is value-creating, not value-destroying. Reverse-engineering the current price: at $20.88, the market implies either (a) near-zero growth or (b) a sharp margin compression scenario. Given trailing FCF of $326M and a P/FCF of 11.7x, the price essentially ascribes little-to-no terminal franchise value to a business with 118% NRR and 84% revenue concentration in large, sticky pharma/health system clients. The implied expectations appear pessimistic relative to achievable outcomes. Key DCF caveats: (1) capex reported as zero, which understates true reinvestment since Doximity's 'investment' is primarily in R&D and S&M (already expensed); the sales-to-capital ratio is therefore very high because book capital understates true invested capital — this inflates apparent ROIC but is partially real given the genuinely asset-light model. (2) The 12% FCF growth assumption over 5 years requires the business to sustain mid-teens revenue growth AND hold margins flat or expanding — management's own FY2026 guidance (13% revenue growth, 55%+ EBITDA margins) is consistent with this but Q3 guidance (7% growth) and AI investment headwinds introduce downside risk. (3) The $31M litigation settlement and 43%-above-peer risk factor language are real qualitative headwinds but not large enough to materially impair the DCF. (4) Customer concentration (84% of revenue from 121 clients) is a legitimate risk that could accelerate deceleration if pharma budgets tighten. Overall: the price requires an excessively pessimistic scenario to be justified, the bear-case DCF still shows 31% upside, ROIC exceeds WACC, and the asset-light model genuinely supports high FCF conversion. This is a pass, but conviction is held back by near-term growth deceleration signals and AI cost ramp uncertainty.

Key points

Bear-case DCF ($27.31) still implies 31% upside from $20.88 — margin of safety survives conservative inputs
ROIC of 17.3% comfortably exceeds WACC of 10.7% — growth is genuinely value-creating on incremental capital
FCF margin of 50.6% and zero capex (asset-light R&D/S&M expense model) produce $326M trailing FCF — P/FCF of 11.7x is undemanding for this cash conversion rate
12% FCF growth assumption is modestly below the 15.45% 3-year revenue CAGR — not heroic; consistent with management's FY2026 13% revenue guidance
2.5% terminal growth rate is below nominal GDP — terminal value is large (71.9%) but consistent with a durable recurring-revenue platform
Reverse-engineered implied expectations at $20.88 are near-zero-growth, which appears overly pessimistic given 118% NRR and sticky large-customer base
WACC of 10.7% is defensible: beta 1.28, no debt, appropriate cost of equity for a mid-cap healthcare SaaS with policy exposure

Red flags

Capex reported as $0 — true reinvestment (R&D + product development) is expensed, overstating FCF yield; economic reinvestment is real even if accounting treats it as opex
Terminal value is 71.9% of EV — highly sensitive to terminal growth and WACC assumptions; a 100bps WACC increase or 50bps terminal growth cut would materially reduce intrinsic value
Q3 FY2026 guidance of only 7% growth vs. DCF-assumed 12% CAGR creates a 1-2 quarter disconnect; if AI cost ramp delays revenue recognition, near-term FCF could undershoot
Customer concentration risk: 84% of revenue from 121 clients means loss of 5-10 large customers could permanently reset the growth trajectory and terminal value
$31M settlement and 43%-above-peer 10-K risk language signal litigation overhang and management credibility damage — qualitative discount warranted
AI margin compression explicitly flagged by management for H2 FY2026; if EBITDA margins compress from 60% toward 50%, FCF growth will lag revenue growth in near term
Stock at 52-week high per price data ($20.88 = 52w high), yet narrative says down 75% from all-time highs — data inconsistency suggests price data may be stale/incorrect; current price context is uncertain

Charlie Munger — 🟢 pass · 74/100 · medium confidence

Doximity is a genuinely understandable business — it runs the dominant professional network for U.S. physicians (approximately 80%+ of doctors on the platform), monetized primarily through pharmaceutical advertising/marketing spend and workflow tools. The unit economics are simple: build a sticky network, charge pharma companies for access to prescribers. This sits within my circle of competence as a network-effect media/platform business analogous to a professional trade publication with massive switching costs baked in.

The quality indicators are compelling: 92% gross margins, 33% operating margins, 50% FCF margins ($326M FCF on $645M revenue), and a 118% net revenue retention rate. ROIC of 17% and ROE of 20% exceed my 15% threshold, though both bear watching given the revenue slowdown. The balance sheet is fortress-like — total liabilities of only $178M against $993M current assets, effectively zero debt, and $879M in cash/investments. The business can be killed by a bad year and still survive easily. Inversion test: this goes to zero only if pharma abandons physician-targeted marketing entirely (implausible) or a competitor replicates the physician trust network (extremely hard given network effects and 15+ years of physician habit formation).

The moat is real and identifiable: physician network effects (each additional doctor increases value for pharma buyers and vice versa), high switching costs (doctors use daily workflow tools — Dialer for 300K+ visits/day, clinical messaging), and data advantages (prescribing patterns across 80%+ of U.S. doctors). The 118% NRR demonstrates pricing power — existing customers spend more each year.

However, several Munger-style concerns temper enthusiasm. First, the recent $31M securities settlement for alleged misrepresentation of user engagement (2021–2023) is a yellow flag on management candor — exactly the kind of credibility issue I take seriously. Second, risk-factor language 43% above peer average in the 10-K, with flagged AI operational/regulatory risks and management turnover, suggests the business is in meaningful transition. Third, the AI cost investment is compressing margins — management guiding from 60% to 55%+ adjusted EBITDA, and the true economic cost of building an AI platform on top of the network is not yet clear. Fourth, revenue growth has decelerated from 23% (Q2) to 7% guided (Q3), and the full-year is 13% — not alarming but suggesting the core pharma advertising market may be maturing.

On valuation: at $20.88, the stock trades at 11.7x FCF and 19.5x trailing P/E — genuinely reasonable for a 92% gross margin business with network effects. The DCF intrinsic value of $33.26 (base case) implies 59% upside with a 12% FCF growth assumption, which seems achievable given historical CAGR of 15.5%. Even the bear case at $27.31 offers 31% upside. For a Munger-style investor, paying 11.7x owner earnings for a dominant professional network with 118% NRR and fortress balance sheet is not overpaying. The price has been beaten down 75% from highs due to earnings misses, settlement noise, and AI cost concerns — creating what appears to be a fair entry for a quality franchise.

The reservations keeping this from a higher score: the management credibility question from the settlement is not trivial; the AI transition creates temporary opacity on true unit economics; and Q3 guidance of only 7% growth is uncomfortably slow for a business still priced with growth expectations. I would want to hold this for 5+ years with low activity and trust the network effects to compound — but management must demonstrate trustworthiness, which the settlement calls into question.

Key points

Dominant physician network with ~80%+ U.S. doctor penetration creates genuine, durable network effects — new doctors increase value for pharma buyers, creating a self-reinforcing moat analogous to a great trade publication with switching costs
92% gross margins, 50% FCF margins ($326M on $645M revenue), 17% ROIC, 118% NRR — these are the hallmarks of a great business, not a mediocre one dressed up
Balance sheet is a fortress: $993M current assets vs $149M current liabilities, effectively zero debt — this business survives any downturn without capital impairment
11.7x FCF and 19.5x trailing P/E is genuinely fair for this quality — DCF base case of $33.26 implies 59% upside even with conservative 12% FCF growth; bear case still implies 31% upside
Circle of competence: business model is simple and understandable — build physician trust network, monetize through pharma marketing access; could explain it in one sentence
AI workflow tools (scribe 3x growth, 300K daily telehealth calls) and 40% of bookings now AI-optimized suggest platform evolution is real, not just narrative
Share repurchases active ($21.9M in Q2, $280M remaining) — rational capital allocation from a management team that understands they have no better investment than their own undervalued equity

Red flags

$31M securities settlement for alleged misrepresentation of user engagement/KPIs (2021–2023 period) — management candor red flag; Munger places enormous weight on trustworthiness and this is a genuine yellow card
Revenue growth decelerating sharply: Q3 FY2026 guidance only 7% growth — if this is structural rather than timing-related, the compounding thesis weakens materially
Risk-factor language 43% above peer average in latest 10-K, explicitly flagging management turnover, AI operational/legal risks, and concentrated customer revenue (84% from 121 customers) — unusual transparency about fragility
AI infrastructure costs expected to compress margins from 60% to 55%+ adjusted EBITDA — the true economic cost of the AI transition is not yet visible in reported numbers, creating temporary opacity on owner earnings quality
Customer concentration: 121 customers ($500K+ ARR) representing 84% of revenue — losing 5-10 clients would be material; pharma budget cycles and policy uncertainty (D2C advertising scrutiny) add volatility to this concentration risk
Stock down 75% from 2021 highs partly reflects prior overvaluation at IPO bubble pricing, but also reflects genuine business model questions — some of the decline is valuation normalization, not margin of safety creation

Michael Mauboussin — 🟢 pass · 74/100 · medium confidence

Doximity presents a genuinely compelling quality case through the Mauboussin lens, though with meaningful uncertainty around moat durability and current expectations pricing. Starting with ROIC vs WACC: ROIC is reported at 17.3%, WACC estimated at 10.7% — a spread of ~660bps. This is a real, positive spread, not a marginal case. ROE is 20%, operating margin 33%, and FCF margin an extraordinary 50.6%. These are not lucky outlier margins; they've been persistent across the 5-year history shown (FCF margin 36% in 2021, expanding to 51% in 2025). The moat analysis is the crux. I identify three real, mechanistic sources: (1) Network effects — demand-side, direct. The physician network (1M+ users, all-time record prescribers in Q2 FY2026) becomes more valuable as density increases. A pharma company's marginal dollar of HCP reach goes further on Doximity as physician adoption rises. This is self-reinforcing and hard to replicate absent a cold-start solution. (2) Switching costs — Doximity is embedding itself into clinical workflow (EHR-adjacent scribing, telehealth Dialer at 300K+ daily calls, drug reference via Pathway). Each embedded tool raises the cost of departure for both physicians (who lose workflow integration) and pharma clients (who lose targeting precision and NRR-supportive analytics). 118% net revenue retention is the revealed preference — customers are expanding, not churning. (3) Data/intangible moat — physician engagement data is a proprietary asset that compounds. Pharma advertisers pay for targeted reach and outcome measurement; Doximity's longitudinal prescriber data creates a feedback loop that generic platforms cannot easily replicate. The CEO's claim that blind physician preference tests favor DOCS on AI answer quality is directionally consistent with the Pathway + Research Solutions integration (2,000+ journals, sub-1-second response), but I cannot independently verify this from the fact base. Rate the moat: Narrow-to-Wide, currently strengthening, with the AI/workflow integration as the leading positive indicator and customer concentration (84% from 121 clients) as the leading vulnerability indicator. Now to expectations investing — what does the price embed? At $20.88, the stock trades at P/FCF of 11.7x, P/E of 19.5x, and P/S of 5.9x. The DCF using 12% FCF growth and 10.7% WACC yields intrinsic value of $33.26 — 59% upside in the base case. Even the bear case DCF is $27.31, implying the current price embeds significant pessimism already. What must be true at $20.88? Working backwards: at ~11.7x FCF, the market is pricing essentially zero or very modest growth — a mature, slowly declining franchise. This seems inconsistent with 118% NRR, AI tool adoption (50% QoQ QAU growth), and a 3-year revenue CAGR of 15.5%. The embedded expectations appear too pessimistic relative to the demonstrated track record, which is the classic Mauboussin buy signal. However, I must apply the outside view. The base rate for SaaS businesses with 30%+ operating margins and 15% growth: these margins do mean-revert. The $31M litigation settlement covering alleged misstatement of KPIs (2021-2023) is a genuine credibility concern — if prior engagement metrics were overstated, what is the true stickiness? The 10K's risk-factor language is 43% above peer average, flagging AI regulatory risk, customer concentration, and management turnover. Soft Q4 guidance and AI cost ramp create near-term earnings pressure. The AI investment thesis is real but early — scribe users tripled but from an unspecified base; AI revenue contribution is not yet material. Probability distribution: Bull (35%) — AI workflow integration accelerates, NRR sustains 115%+, pharma budgets recover, stock reaches $35-45 range. Base (45%) — Steady 10-13% growth, margins compress modestly to 50-55% FCF margin as AI costs rise, stock reaches $28-33. Bear (20%) — Pharma budget cuts from policy uncertainty, AI competition from Epic/ambient scribe competitors erodes switching costs, NRR falls below 100%, stock tests $15-17. The fat tail risk is on the downside: customer concentration means losing 10-15 of the 121 large clients would be structurally material. Score 74 — above my 70 threshold for pass, but not a high-conviction wide-moat franchise buy. The price is cheap relative to the quality of the business; the moat is real but narrower than the gross margin implies; and near-term execution risk (AI cost ramp, guidance softness, policy headwinds) warrants an honest watch component. The DCF margin of safety is genuine, moat mechanisms are identifiable, and 118% NRR is hard evidence of switching costs — these push me over the pass threshold.

Key points

ROIC of 17.3% vs WACC of 10.7% — 660bps spread, persistent across 5-year history; FCF margin expanding from 36% (2021) to 51% (2025), not lucky outlier
Three mechanistic moat sources identified: (1) direct physician network effects (density compounds pharma targeting value), (2) workflow switching costs (EHR-adjacent scribing, telehealth, drug reference — 118% NRR is revealed preference), (3) proprietary longitudinal prescriber data asset
Expectations investing signal is bullish: P/FCF of 11.7x embeds near-zero growth for a business with 15.5% 3-year revenue CAGR, 118% NRR, and demonstrable AI product momentum — market appears overly pessimistic
DCF base case ($33.26) implies 59% upside; even bear case ($27.31) is 31% above current price — margin of safety exists across most of the distribution
AI integrated programs growing from <5% to 40% of bookings in one year is a real leading indicator of moat deepening, not a lagging metric
Customer concentration (84% revenue from 121 clients at $500K+ ARR) is simultaneously a moat indicator (stickiness) and a concentration risk; NRR is the key monitoring metric

Red flags

$31M litigation settlement covering alleged misstatement of user engagement KPIs (2021-2023) is a genuine management credibility concern — raises inside-view doubt on reported engagement metrics; outside view says companies that misstate KPIs once bear watching
Customer concentration creates a fat tail: 121 clients representing 84% of revenue means 10-15 defections would be structurally material; this is the primary bear tail risk
AI cost ramp explicitly flagged by management for H2 FY2026 — FCF margin of 51% likely to compress; 10K risk-factor language 43% above peer average citing AI operational, regulatory, and third-party dependency risks
Soft Q3 guidance (7% growth) and policy/D2C budget uncertainty create near-term earnings pressure that could reset market expectations downward before the AI thesis matures
Moat trajectory depends on AI competition not replicating the physician network — Epic, ambient scribe vendors, and general LLMs could erode switching costs if workflow tools become commoditized; this is the key moat-erosion risk to monitor
Pathway acquisition value and AI revenue contribution not yet quantified — investment phase without clear monetization timeline means near-term ROIC dilution from AI R&D spend is possible

Forensic Short-Seller (Chanos/Einhorn-style) — 🟢 pass · 72/100 · medium confidence

Doximity is an unusual target for a forensic short lens because the accounting quality is actually quite high. The core Chanos test — net income vs. operating cash flow — comes back clean or better than clean: FCF of $326M exceeds net income of $196M, implying no accrual stuffing. FCF margin of 50.6% vs. net margin of 30.4% is a structure we reward on the long side forensically. Revenue CAGR of 15.5% over 3 years is moderate, not explosive. Capex is reported as $0 (likely software-light SaaS), so FCF equals OCF. However, several genuine forensic flags warrant a 'watch' posture rather than a clean pass: (1) The $31M securities fraud settlement covering 2021-2023 — alleging misstatement of user engagement and KPIs — is a documented prior credibility breach, the exact type of accounting/disclosure integrity issue the short lens cares about most. (2) Risk-factor language 43% above peer average in the 10-K (per discussion thread) specifically flagging AI operational/legal/regulatory risks, third-party model dependencies, and management turnover — insider awareness of elevated disclosure risk. (3) SBC dilution check is incomplete from available data: buybacks of $21.9M in Q2 vs. ongoing RSU grants (CFO Form 3 filing shows 499,722 RSUs just disclosed June 2026; President received 55,524 RSUs) — need to verify net share count trend to confirm buybacks aren't merely a treadmill. (4) Customer concentration: 84% of revenue from 121 customers makes revenue recognition and retention claims critical — a few large contract renegotiations could be catastrophic. (5) AI cost capitalization: fact base notes $0 capex, but AI infrastructure investment is being flagged as a rising cost in H2 — need to confirm these aren't being capitalized to mask expense. The bear kill question: what would make this a short? A restatement or SEC inquiry into prior KPI/engagement misstatements (the $31M settlement suggests regulatory interest), evidence that buybacks are failing to reduce share count net of SBC (treadmill dilution), or discovery that AI infrastructure costs are being capitalized rather than expensed. The bull disproof: FCF continues to exceed net income, share count is actually declining net of SBC, and no further regulatory action follows the settlement. On balance, the forensic picture is materially cleaner than most growth names — the cash-exceeds-earnings structure is anti-fraud — but the prior settlement, governance flags, and SBC/buyback treadmill risk prevent a strong pass.

Key points

FCF ($326M) materially exceeds net income ($196M) — the core forensic test is clean; earnings are understating cash generation, not overstating it
FCF margin of 50.6% vs. net margin of 30.4% implies no accrual stuffing — this is structurally opposite to the classic short profile
Reported $0 capex in a software business is consistent with expense-as-you-go model, not aggressive capitalization — but AI infrastructure ramp in H2 needs monitoring
Revenue growing at ~15% CAGR while FCF growing faster (from $124M in 2021 to $326M in 2025) — unit economics improving, not deteriorating
Current ratio of 6.6x, no debt (debt-to-equity null), $64M cash plus likely large investment portfolio — no financing dependence or debt wall risk
$31M securities fraud settlement (2021-2023 period) is a documented prior disclosure integrity breach — prior misstatement of user engagement KPIs is a credibility scar
Risk-factor language 43% above peer average in 10-K — management itself flagging elevated AI, legal, regulatory, and management turnover risks
CFO Form 3 discloses 499,722 RSUs just issued — large ongoing SBC grants require share count verification to confirm buybacks are accretive, not treadmill

Red flags

$31M settlement alleging misstatement of user engagement and growth metrics (2021-2023) — a forensically significant prior credibility event; regulatory/SEC follow-on risk cannot be ruled out
SBC treadmill risk unconfirmed: CFO granted ~500K RSUs, President granted 55K RSUs in June 2026 alone; $21.9M Q2 buyback may not offset total annual SBC — net share count trend not verifiable from available data
AI infrastructure costs explicitly flagged as rising in H2 FY2026 — if any portion is being capitalized (vs. expensed), this would mask margin compression; $0 reported capex needs reconciliation with disclosed investment ramp
Customer concentration (84% revenue from 121 customers) makes revenue recognition integrity critical — a handful of contract disputes or non-renewals could produce a revenue cliff that lagging indicators (DSO, NRR) might not anticipate
Management turnover flagged in 10-K risk factors — CFO is new (Form 3 filed June 2026 suggesting recent appointment); CFO/auditor turnover is a classic governance red flag in the Chanos checklist
Prior KPI inflation allegations (engagement, user activity) suggest management may be promotional — CEO language ('taking it all the way', 'winning decisively' on blind tests) and AI adoption metrics (QAU growth cited from undisclosed base) warrant skepticism

Chuck Akre — 🟡 watch · 62/100 · medium confidence

Doximity checks two of the three legs of the stool convincingly — extraordinary business economics and capital-light franchise — but the third leg (management integrity and reinvestment runway) carries meaningful clouds that prevent a full pass. On the business quality side, DOCS is exceptional: 92% gross margins, ~51% FCF margins ($326M FCF on $645M revenue), 33% operating margins, ROIC of ~17% and ROE of ~20%, all achieved with essentially zero debt (debt/equity null, current ratio 6.6x, net cash position). The physician network moat — 1M+ users, 118% NRR, 84% of revenue from 121 large customers at $500K+ ARR — reflects genuine switching costs and network effects. This is a capital-light franchise with real pricing power in a specialized, sticky B2B market. FCF per share is growing: FCF rose from $125M in FY2021 to $326M in FY2025, a strong compounding trajectory. The DCF intrinsic value of $33.26/share vs. current price of $20.88 implies ~59% upside, with even the bear case ($27.31) comfortably above market — suggesting the price is reasonable relative to the compounding rate. Price-to-FCF of 11.7x for a ~50% FCF margin business with 15% revenue CAGR is not demanding. However, material concerns temper enthusiasm on the integrity/management leg: (1) the $31M securities litigation settlement (June 2021–Aug 2023) for alleged misstatement of user engagement and KPIs is a direct integrity red flag — this is exactly the kind of 'not honest with owners' pattern Akre finds disqualifying; (2) 10K risk-factor language is 43% above peer average, with explicit flags on management turnover, AI regulatory risk, and third-party model dependency; (3) Q4 FY2026 guidance implies deceleration, and management's language around 'policy uncertainty' and 'measured approach' to unbooked revenue is vague and offers limited visibility; (4) AI margin compression is beginning — management flagging rising R&D/infrastructure costs pulling adjusted EBITDA from 60% toward 55% target; (5) the reinvestment runway via AI is real but early-stage and unproven at scale — AI tools are growing users but not yet materially contributing to revenue, so the 'reinvest at high rates' thesis is partly speculative. Capital allocation has been reasonable (buybacks at depressed prices are value-accretive, Pathway acquisition was small and strategic), but the prior credibility damage from the settlement makes assessing management skill and honesty harder. The business deserves a watch rather than avoid given genuinely exceptional economics, but cannot earn a full pass until management restores credibility and the AI reinvestment thesis proves out in revenue terms.

Key points

Extraordinary FCF economics: 51% FCF margin, $326M FCF on $645M revenue, essentially no debt — pure capital-light franchise
ROE ~20%, ROIC ~17% achieved without leverage — passes the 'genuine business economics' test cleanly
118% NRR and 84% revenue concentration in 121 large accounts signals deep switching costs and expanding relationships
Price-to-FCF of 11.7x is undemanding for a business of this quality; DCF base case $33.26 implies 59% upside from $20.88
FCF per share compounding: FCF grew from $125M (FY2021) to $326M (FY2025) — 4-year CAGR ~27% in absolute FCF
AI reinvestment runway (scribe, integrated programs, Docs GPT) represents a credible, early-stage opportunity for high-return capital redeployment
Active buybacks ($21.9M in Q2, $280M remaining) at depressed prices are capital-allocation positive

Red flags

$31M securities litigation settlement for alleged misstatement of user engagement/KPIs (2021–2023) — direct integrity red flag, the most disqualifying concern for Akre
10K risk-factor language 43% above peer average: management turnover, AI regulatory risk, third-party dependencies explicitly flagged
Q3 FY2026 guidance implies only 7% revenue growth — meaningful deceleration from 23% in Q2; management 'timing' explanation plausible but unverifiable
AI investment ramp expected to compress adjusted EBITDA from 60% toward 55% — margin direction is wrong near-term
Customer concentration risk: 84% of revenue from 121 customers; losing 2–3 large clients would be materially damaging
Vague 'policy uncertainty' language around pharma/D2C budgets with no quantified downside scenario — opacity about a known risk
AI revenue contribution not yet material; reinvestment-at-high-rates thesis for AI is forward-looking and unproven in revenue terms

Warren Buffett — 🟡 watch · 62/100 · medium confidence

Doximity is a genuinely interesting business with characteristics I find appealing: a dominant physician network (1M+ physicians, ~80% of US doctors), extraordinarily high gross margins (~92%), exceptional FCF conversion (50%+ FCF margin), no debt, and a current ratio above 6x. The NRR of 118% and 84% revenue concentration in large enterprise clients suggest real switching costs and genuine customer value delivery. These are hallmarks of a quality business with network effects — once physicians are on the platform and pharma clients are measuring ROI through it, the friction to leave is considerable. The ROE of 20% and ROIC of 17.3% without leverage are solid, though not exceptional for a software business of this quality. The FCF/share economics are genuinely good: $326M FCF on a $3.8B market cap implies a price-to-FCF of ~11.7x, which is not expensive for a business of this caliber. The DCF at $33.26/share (base) versus $20.88 current price suggests meaningful upside even with modest 12% FCF growth assumptions. However, several things give me pause. First, the business model sits at the edge of my circle of competence — the AI pivot, pharma advertising dynamics, and regulatory environment for physician-facing digital tools require more specialized knowledge than I typically possess. Second, the $31M securities settlement for allegedly misleading investors about engagement KPIs is a yellow flag on management candor — honest managers don't overstate metrics. Third, risk-factor language in the 10K is 43% above peer average, flagging AI operational risks, third-party dependencies, management turnover, and litigation. Fourth, the stock is at 52-week lows with soft Q3/Q4 guidance and margin compression from AI investment, meaning near-term earnings power may be weaker than trailing figures suggest. Fifth, growth is decelerating toward 13% revenue CAGR, and I'd want to see whether pharma advertising spend — the core revenue driver — has genuine durability or is cyclically exposed to policy/budget uncertainty. The moat appears real but narrower than a See's Candies or Coca-Cola: it depends on continued physician engagement, pharma marketing budget allocations, and execution on AI — all of which carry more uncertainty than I prefer. At 11.7x FCF and 19.5x P/E, the price is fair but not screamingly cheap given these risks. I would not pay up significantly for this level of uncertainty. A wonderful business at a fair price — this is a fair business at a fair price, trending toward wonderful if the AI platform delivers. I'd watch rather than act now.

Key points

92% gross margins and 50%+ FCF margins indicate exceptional unit economics and near-zero marginal cost of software delivery — a hallmark of quality
118% net revenue retention demonstrates genuine customer value and real switching costs; pharma clients expand spend year over year
Zero debt, $878M cash on balance sheet, current ratio of 6.6x — fortress balance sheet that can self-fund through downturns
20% ROE and 17.3% ROIC achieved without leverage are solid; each retained dollar appears to create real value
Price-to-FCF of 11.7x is genuinely reasonable for a business of this quality; DCF base case at $33.26 implies 59% upside
Share buybacks active ($280M remaining authorization) — capital return mechanism present, though I'd want to verify these are below intrinsic value
Network effects are real: 1M+ physician users creating a two-sided marketplace where both doctors and pharma advertisers benefit from scale
Revenue CAGR of 15.5% over 3 years shows consistent compounding, though decelerating

Red flags

$31M securities settlement for allegedly misleading investors about engagement KPIs and user activity — a direct challenge to management candor and integrity, which I weight heavily
10K risk-factor language 43% above peer average signals management acknowledging elevated complexity and uncertainty — opaque risk profile
Business model partially outside my circle of competence: AI-driven pharma advertising dynamics, regulatory exposure for physician-facing tools, and dependency on third-party AI models are difficult to forecast a decade out
Growth decelerating to 13% guidance with Q3 at only 7%; soft guidance combined with rising AI investment costs suggests near-term margin compression
Customer concentration risk: 84% of revenue from 121 clients means losing even 5-10 large accounts would be materially damaging
Prior management credibility damage (settlement period 2021-2023) coincides with period of alleged KPI inflation — raises questions about whether current metrics are conservatively stated
Stock at 52-week highs per price data but news context suggests recent 25% single-day plunge post-earnings with shares near all-time lows — significant price signal inconsistency in data quality
Policy/regulatory uncertainty around D2C pharmaceutical advertising could impair core revenue stream in ways management cannot quantify

Philip Fisher — 🟡 watch · 62/100 · medium confidence

Doximity presents a genuinely interesting Fisher-style growth candidate — a physician network with real network effects, above-average margins, and a credible AI product pivot — but several key Fisher criteria are either imperfectly met or obscured by missing data. The 3-year revenue CAGR of 15.5% is respectable, and the shift to AI-integrated programs (40% of Q2 FY2026 bookings) suggests genuine product innovation rather than mere price-taking. The 92% gross margin and 50%+ FCF margin are exceptional and suggest real pricing power and scale economics. Net revenue retention of 118% is a strong scuttlebutt proxy — customers are expanding spend, which Fisher would view as validation of product quality. However, Fisher's framework demands much more than margin quality. Several concerns weigh heavily: (1) Growth is decelerating — Q3 FY2026 guidance implies only 7% YoY growth, down sharply from 23% in Q2, and the FY2026 midpoint of 13% is declining. For Fisher, the multi-year runway must be credibly accelerating or at least sustained, not visibly tapering. (2) The $31M securities settlement alleging misstatement of user engagement KPIs is a serious Fisher red flag on management candor and integrity. Fisher prized honesty above almost everything — management that inflated metrics violates the core of his scuttlebutt method. (3) R&D spend levels are not broken out clearly in the fact base (capex listed as zero, which is suspicious for a technology company — likely expensed into opex), making it impossible to evaluate whether Doximity is investing adequately for its next growth phase. (4) Management turnover flagged in the 10-K risk factors (43% above-peer risk language) and prior executive departures noted in litigation context suggest bench depth concerns. (5) AI investment ramp is real but early — scribe users tripled but from an undisclosed base; revenue contribution from AI is not yet material. Fisher would want to scuttlebutt the clinical adoption curve more rigorously before conviction. The bull case on Fisher terms is real: a defensible physician platform, genuine AI product differentiation (Docs GPT, Pathway integration, Research Solutions partnership), 118% NRR suggesting customers genuinely value the product, and CEO credibility on long-term AI vision. But the combination of decelerating growth, management integrity questions from the settlement, and thin public evidence on R&D investment levels keeps this a 'watch' rather than a conviction 'pass.'

Key points

15.5% 3-year revenue CAGR with 118% net revenue retention signals genuine organic growth and customer value expansion — core Fisher criteria
92% gross margin and 50%+ FCF margin indicate exceptional pricing power and scale economics consistent with a durable competitive moat
AI-integrated programs grew from <5% to 40% of bookings in ~1 year — credible evidence of productive R&D translating into new products and new revenue mechanisms
121 customers at $500K+ ARR comprising 84% of revenue represents deep, expanding customer relationships Fisher would view positively
Pathway acquisition and Research Solutions partnership show management actively building a multi-year product roadmap beyond current lines — consistent with Point 3 on future growth plans
Share repurchase ($280M authorization remaining) rather than dilutive equity issuance suggests capital discipline and confidence in FCF durability

Red flags

Q3 FY2026 guidance of only 7% growth vs 23% in Q2 represents sharp deceleration — Fisher's multi-year runway requires sustained, not episodic, above-average growth
$31M securities settlement (2021-2023 period) for alleged misstatement of user engagement KPIs is a direct Fisher red flag on management honesty and candor — the most serious concern
10-K risk factors running 43% above peer average in word count, with management turnover explicitly flagged, suggests bench depth and organizational integrity concerns
R&D investment levels not transparently disclosed (capex reported as $0, suggesting full expense treatment but no breakout); impossible to verify Fisher's criterion of productive, sustained R&D commitment
Policy uncertainty on pharma D2C advertising budgets creates near-term revenue visibility risk; management acknowledged 'measured approach' to unbooked Q4 revenue — evasive language Fisher would scrutinize
Customer concentration risk: losing even a handful of the 121 large customers could be material to results, limiting compounding durability
Stock down 75% from highs with JPMorgan maintaining Neutral at $26 — market skepticism about growth re-acceleration is not obviously wrong given guidance trends

Joel Greenblatt — 🟡 watch · 58/100 · medium confidence

Doximity is a genuinely high-quality operating business that scores well on the ROIC axis but only moderately on the earnings yield axis at current prices. Let me work through the Magic Formula inputs. For ROIC (Greenblatt-style): EBIT = $214.9M. Net working capital = current assets - current liabilities = $993.5M - $149.8M = $843.7M. Net fixed assets: the company is nearly asset-light with $0 reported capex, so tangible fixed assets are minimal. However, the large current assets are dominated by cash and short-term investments (~$65M cash plus likely significant marketable securities in the $993M current asset pool), which inflates the NWC figure artificially. Stripping excess cash conservatively, net working capital employed is actually quite modest for this SaaS business — but the ROIC denominator is difficult to pin down precisely from available data. Using the reported ROIC of 17.3% (per fundamentals) or the operating margin of 33.3% on a very asset-light base, this is clearly a high-ROIC business — potentially >100% on tangible capital excluding excess cash, consistent with a network-effect software platform. For earnings yield: EV = market cap ($3.82B) + debt (minimal, D/E is null suggesting near-zero debt) - excess cash ($64.8M cash, but balance sheet shows $993M current assets suggesting far more in short-term investments) = roughly $3.82B net of cash/investments. Using $879M cash on balance sheet per narrative vs $64.8M in the fundamentals data (discrepancy noted — likely the $64.8M is just cash equivalents, broader liquid holdings are ~$878M per Q2 call), adjusted EV ≈ $3.82B - $0.88B = ~$2.94B. EBIT/EV = $214.9M / $2.94B ≈ 7.3% earnings yield. This is decent but not screaming cheap — it's around fair value for a quality business, not a bargain. The DCF base case of $33.26 intrinsic value (59% upside to $20.88) is encouraging, and the bear case of $27.31 still implies ~31% upside. Price/FCF of 11.7x is genuinely attractive. The business scores highly on quality (capital-light, 50%+ FCF margins, 92% gross margin, 118% NRR, virtually no debt) but only moderately on price. Key concerns: (1) near-term growth deceleration (Q3 guidance only 7%), (2) AI margin investment compressing EBITDA from 60% toward 55%, (3) $31M litigation settlement suggesting prior KPI credibility issues, (4) 43% above-peer risk factor language in 10-K. No special situation catalyst present — this is a straightforward quality-at-moderate-price evaluation. On the Magic Formula dual-axis: ROIC = excellent (top quintile); earnings yield = moderate-to-decent (~7%), not deep value. Combined ranking: good but not great. Score of 58 reflects a quality business trading at a reasonable but not compelling discount — a 'watch' until price improves or growth re-accelerates to justify higher confidence.

Key points

EBIT of $214.9M on near-zero tangible fixed assets = extremely high Greenblatt ROIC (likely >100% on true tangible capital)
Earnings yield ~7.3% (EBIT/$2.94B adjusted EV) — decent but not deeply cheap by Magic Formula standards
FCF/price yield of ~8.5% (P/FCF = 11.7x) is the most attractive valuation metric; 50%+ FCF margin is exceptional
Zero debt, ~$878M in liquid assets, current ratio 6.6x — fortress balance sheet with no EV distortion from leverage
DCF intrinsic value $33.26 (base) vs $20.88 price = ~59% upside; bear case $27.31 still implies meaningful margin of safety
118% NRR and 84% revenue concentration in 121 large customers signals sticky, expanding relationships — durable economics
Revenue CAGR 15.5% over 3 years with 33% operating margins — quality business metrics clearly above average

Red flags

Earnings yield (~7%) ranks only moderately on the cheap axis — not a screaming Magic Formula bargain
Near-term growth deceleration: Q3 FY2026 guided at only 7% YoY, FY2026 full year ~13% — below recent trend
$31M investor settlement covering 2021-2023 period suggests prior KPI/engagement metric overstatement — EBIT reliability concern
10-K risk factor language 43% above peer average flagging AI regulatory/legal exposure, management turnover, customer concentration
AI infrastructure investment expected to compress EBITDA margins from 60% toward 55% — ROIC directionally pressured
No special situation catalyst (no spinoff, restructuring, or forced-selling dynamic) — purely a quality-price tradeoff
Cash balance discrepancy in fact base ($64.8M reported vs ~$878M per earnings call) creates minor EV calculation uncertainty

Bruce Greenwald — 🟡 watch · 58/100 · medium confidence

Doximity is a high-margin, capital-light SaaS business with a real operating history and meaningful earnings power, making EPV analysis directly applicable. Normalizing: operating income ~$215M on ~$645M revenue (33% GAAP margin); FCF margin is 50.6% but reported capex shows $0 (suggesting no maintenance capex distinction is being made — all FCF looks distributable). Adjusting for stock-based compensation as a real cost (SBC is substantial for SaaS companies; not broken out here but typically 15-25% of revenue at this scale — this fact base is silent, a meaningful gap), NOPAT normalized conservatively might run $170-190M. Capitalizing at WACC of ~10.7% gives EPV of roughly $1.59-1.78B. With ~183M diluted shares and net cash of ~$65M, EPV per share lands around $8.90-$9.97 per share — well below the $20.88 current price. Even being generous with normalized NOPAT (using $215M operating income tax-affected at ~25% = ~$161M NOPAT, or using FCF of $326M at face value), FCF/WACC capitalizes to ~$3.05B enterprise value, or roughly $16.60/share — still below market price. The DCF provided yields $33.26/share but 72% of that value sits in the terminal value, exactly the kind of far-future assumption I distrust. The asset reproduction case: Doximity's moat is real but hard to price. Rebuilding the physician network (80%+ of US physicians), clinical workflow integrations, and brand trust would be enormously costly — network effects and customer captivity (habit, switching costs in daily workflow tools) are genuine. EPV substantially exceeds reproduction value of tangible assets (~$979M book equity, mostly cash/investments), which is the right signal for a franchise. The gap between EPV and price, however, is occupied entirely by growth assumptions — 12% FCF growth baked into the DCF, not EPV. The moat is credible but being tested: AI cost pressures are compressing margins, the $31M litigation settlement signals past KPI credibility issues, 10-K risk factors are 43% above peer average, and near-term guidance (7% Q3 growth) suggests deceleration. Customer concentration (84% from 121 customers) creates lumpiness risk. The business earns above-cost-of-capital returns (ROIC 17.3% vs WACC 10.7%), consistent with franchise value, but the price still requires substantial growth to be realized and sustained inside the moat. On pure EPV math the stock is not cheap enough for a margin-of-safety buy; on the franchise/moat view there is strategic merit worth watching if price compresses further toward EPV.

Key points

EPV estimate (FCF capitalized at WACC): ~$3.05B EV or ~$16-17/share at face-value FCF; current price at $20.88 provides no margin of safety on an EPV basis
ROIC of 17.3% meaningfully exceeds WACC of 10.7%, consistent with a genuine franchise — EPV >> tangible reproduction value (book ~$979M mostly cash), confirming real barriers
Moat is identifiable and concrete: physician network captivity (80%+ US physician penetration), daily workflow habit (Dialer 300K+ daily calls, scribe tripling users), switching costs in integrated programs, and high NRR of 118%
72% of DCF value sits in terminal value — the gap between EPV and market price is entirely a growth bet, not an earnings-power story; at $20.88 the market is paying for growth
Normalized FCF margins are exceptional (50%+) but SBC not quantified in fact base — a real cost that would reduce true distributable earnings; confidence penalized for this data gap
$31M litigation settlement for alleged KPI misstatement (2021-2023) is a credibility flag on reported engagement metrics; risk factors 43% above peer average signals elevated uncertainty
AI margin pressure (management guiding to increased R&D/infrastructure costs H2 FY2026) threatens the normalized margin assumption; target EBITDA margins declining from 60% toward 55%

Red flags

Market price ($20.88) exceeds EPV per share (~$9-17 depending on SBC adjustment) — the entire premium is growth-dependent, which is only safe inside a well-defended moat that is currently under pressure
SBC magnitude not disclosed in fact base — for SaaS companies this is often 15-25% of revenue, which would materially reduce true normalized distributable earnings and compress EPV further
$31M settlement alleging investor misrepresentation of user engagement (2021-2023) raises concern about reliability of KPI metrics used to assess business strength
Customer concentration risk: 84% of revenue from 121 customers means a handful of pharmaceutical/health system clients withdrawing can be immediately material
AI investment thesis requires sustained above-WACC returns inside a moat that is now facing both AI-enabled competition and pharma budget uncertainty — growth is not free

Peter Lynch — 🟡 watch · 58/100 · medium confidence

Doximity is a understandable business — a physician network monetized through pharma advertising and workflow tools — explainable in one sentence: 'LinkedIn for doctors, monetized by selling pharma companies targeted access to 1M+ physicians.' The earnings story is real and traceable. However, the PEG test is the central concern under my framework. The reported PEG is 1.26, which already exceeds my preferred threshold of 1.0, and the earnings growth picture is complicated. Revenue CAGR is 15.5% over 3 years, but net income actually DECLINED from $223M in FY2024 to $196M in FY2025 — a 12% drop — even as revenue grew 13%. FCF tells a better story ($326M, up from $273M), but EPS growth is clearly decelerating and not clean. The stock trades at P/E ~19.5x on a business where EPS growth is arguably in the 10-15% range at best in the near term, putting the true PEG closer to 1.3-1.9x depending on assumptions. That's stalwart territory, not fast-grower pricing. Category assessment: this is transitioning FROM a fast grower (was 20-25%+ in 2021-2022) TO a stalwart (10-15% revenue growth) with margin pressure from AI reinvestment. For a stalwart, I'd want to buy it at a 30-50% gain opportunity with a reasonable multiple — and the DCF does suggest ~59% upside (intrinsic $33.26 vs. $20.88), which is attractive. The balance sheet is genuinely excellent: zero debt, current ratio 6.6x, $65M cash plus near-$1B in short-term investments implied by current assets, and $326M FCF generating 51% FCF margins. No diworsification red flags — the Pathway acquisition was tiny (6 people). Insider activity (CFO Form 3 with RSUs, President getting RSUs) is neutral to mildly positive. The $31M litigation settlement for alleged KPI misrepresentation (2021-2023 period) is a credibility ding but appears resolved. The biggest Lynch-style concern is that AI margin pressure is real — management flagging rising R&D costs in back half, and Q3 guidance implies only 7% growth. A fast grower slowing to 7% with a 19.5x P/E and rising costs is a dangerous combination. The 'roll-out' formula here — expanding pharma clients into AI-integrated programs — is credible but early-stage. 40% of bookings now in AI-optimized integrated programs is promising but not yet proven at scale for revenue acceleration. The stock is down 75% from highs and trading near 52-week lows ($20.88 = current 52w high per price data, suggesting recent bounce from $17.15 low), meaning the neglected-stock dynamic is emerging. Institutional skepticism (JPMorgan Neutral, $26 target) and low retail conviction are actually Lynch-positive signals if the fundamentals recover. Net: interesting situation, but PEG above 1, decelerating EPS growth, and near-term AI cost headwinds keep this in 'watch' territory. If EPS growth reaccelerates to 20%+ on AI monetization, this becomes a fast-grower buy. For now, I'd want to see one or two quarters of evidence before committing.

Key points

PEG of 1.26 (reported) exceeds my 1.0 threshold; true PEG likely 1.3-1.9x given EPS deceleration — stalwart pricing for a stalwart, not cheap
Business is fully understandable: physician network monetized via pharma targeted advertising + workflow tools, 1M+ physicians, 92% gross margins
Balance sheet is excellent — zero debt, current ratio 6.6x, $326M FCF at 51% FCF margin; internally funds all growth, no leverage risk
Stock down 75% from highs, trading near 52-week lows ($17.15 low), low analyst coverage conviction — Lynch-positive neglected-stock setup emerging
Net income DECLINED 12% YoY (FY2025 $196M vs FY2024 $223M) despite 13% revenue growth — EPS growth story is NOT clean right now
AI integrated programs at 40% of bookings is encouraging roll-out metric, but Q3 guidance of only 7% growth signals near-term deceleration
DCF intrinsic value $33.26 (59% upside) provides margin of safety if FCF growth thesis holds at 12% assumed rate
NRR of 118% and 84% revenue concentration in 121 large customers ($500K+ ARR) is a durable, sticky franchise

Red flags

EPS growth decelerating sharply — net income down 12% in FY2025; Q3 FY2026 guidance only 7% revenue growth
PEG above 1.0 at current earnings trajectory; P/E of 19.5x requires sustained 20%+ earnings growth to justify as fast grower
AI margin pressure explicitly flagged by management — rising R&D/infrastructure costs back half FY2026, EBITDA target dropping from 60% to 55%
$31M litigation settlement for alleged misrepresentation of user engagement KPIs (2021-2023) — credibility overhang and prior disclosure concerns
Risk factor language 43% above peer average in 10-K — management signaling materially elevated operational and regulatory risk
Customer concentration: 84% revenue from 121 clients — losing a handful would be material to financials
Policy uncertainty in pharma ad budgets (D2C scrutiny, 2026 calendar budget still being finalized) adds near-term revenue visibility risk

AI & Disruption Referee (Christensen-style) — 🟡 watch · 58/100 · medium confidence

Doximity sits at a genuinely ambiguous intersection for the Christensen disruption lens. It is NOT a pure intermediary being disintermediated — it is a closed professional network with proprietary identity infrastructure (verified physician credentials), workflow tools, and a pharma advertising marketplace. But its core monetization — selling pharma companies targeted access to physicians — is a matching/optimization function that AI and first-party pharma data could increasingly replicate. The question is whether Doximity's physician network data is a compounding moat or an eroding one.

CORE JOB BEING DONE: Doximity does three separable jobs. (1) It gives physicians a professional identity/communications layer (messaging, e-signatures, dialer, telehealth). (2) It gives pharma/health system marketers targeted, verified reach to specific physician cohorts at scale. (3) It is building an AI clinical workflow layer (scribe, Docs GPT, drug reference). Jobs 1 and 3 are AI tailwinds. Job 2 is the revenue engine (virtually all revenue) and is the disruption risk.

DISINTERMEDIATION MECHANISM — THE REAL RISK: Pharma companies pay Doximity because they cannot efficiently reach and verify the right physicians at scale on their own. Doximity's verified identity graph and behavioral data (prescribing specialty, clinical focus, engagement patterns) is the scarce asset. The disruption scenario: as pharma companies build richer first-party HCP data (through their own portals, CRM, specialty pharmacy data, claims data) combined with foundation models, their willingness-to-pay for Doximity's matching layer could compress. This is not imminent but is a plausible 5-10 year trajectory — especially if hyperscalers (Google Health, Amazon, Microsoft/Azure health) offer competing HCP identity and targeting infrastructure as a bundle. The $31M litigation settlement revealing alleged over-stating of user engagement/KPIs is a yellow flag that the network engagement metrics — the very foundation of pharma willingness-to-pay — may have been softer than claimed.

MOAT ASSESSMENT — COMPOUNDING OR ERODING: The physician identity/credential verification layer is genuinely hard to replicate (state licensing integration, years of physician onboarding) and sticky. The 118% NRR and 92% gross margin confirm real lock-in today. However, the AI tool suite (scribe, Docs GPT) is partially replicable by well-resourced competitors — Epic already has ambient AI scribing partnerships (Nuance/Microsoft DAX), and OpenAI/Anthropic can be embedded by any EHR vendor. Doximity's advantage in AI clinical tools is its distribution (800K+ physicians already on platform) not uniquely proprietary model training data. This is a defensible but not unassailable moat. The pharma matching data IS more proprietary — behavioral engagement from 80%+ of US physicians is hard to replicate — but the question is whether AI makes buyers value it MORE or lets them approximate it with their own data.

MANAGEMENT HONESTY: Management is more credible than average here. They are building AI tools, naming AI margin cost pressures explicitly (back-half R&D ramp, AI infrastructure costs), and framing AI programs as a new product category (40% of Q2 bookings are 'AI-optimized integrated programs'). They are threading a difficult needle: using AI as a product to deepen physician engagement (raising switching costs) while also selling AI-powered targeting to pharma (upgrading the revenue model). This is the right strategic response. However, the 10-K risk factor language being 43% above peer average on AI-related operational, legal, and regulatory risks suggests internal recognition of significant uncertainty the earnings call downplays.

HYPERSCALER THREAT: Microsoft (via Nuance DAX and Epic integration), Google (via Google Health and Med-PaLM), and Amazon (HealthLake) all have ambitions in physician workflow. None has Doximity's community/social layer, but Epic's dominance in EHR (used by ~35% of hospitals) means Microsoft has privileged access to the clinical workflow where physicians spend most of their time. If Epic/Microsoft bundle ambient scribing and clinical AI directly into the EHR workflow, Doximity's standalone scribe and Docs GPT face commoditization pressure from better-placed infrastructure players. The pharma marketing business is more insulated from hyperscaler competition but not immune.

FALSIFIABLE CALL: Disruption is confirmed over 2-4 years if: NRR falls below 110%, pharma customers begin negotiating lower CPMs citing own-data capabilities, AI-native HCP targeting platforms (Veeva, IQVIA Orchestrated Customer Engagement, Komodo Health) gain measurable share, or EHR-bundled AI scribing causes physician engagement on Doximity workflow tools to plateau/decline. Disruption is DISPROVED if: NRR holds at 115%+, pharma integrated program revenue grows above 20% annually (demonstrating AI makes Doximity MORE not less valuable to buyers), and physician daily active usage of AI tools (scribe, Docs GPT) compounds at 50%+ QoQ for 4+ quarters, creating irreplaceable workflow dependency.

CURRENT VERDICT: The business is in a transitional window — the legacy pharma-matching revenue model faces long-run commoditization risk, but Doximity is actively building the physician workflow AI layer that could make it MORE entrenched rather than less. The outcome is genuinely uncertain on a 5-10 year view. This is not a melting ice cube (FCF is real, NRR is high, the network is defensible today) but it is not a compounding moat either. Score 58 reflects real uncertainty — above 'avoid' because the strategic response is credible, below 'pass' because the core revenue is in the riskier matching/intermediary category and AI cost pressures are already visible.

Key points

Verified physician identity graph (800K+ US physicians, 80%+ of US doctors) is genuinely hard to replicate and is the foundational moat — this does compound with AI use
Core pharma-marketing revenue is a matching/optimization function — the highest-risk category under disruption lens — where buyer sophistication and own-data accumulation could compress Doximity's value proposition over 5-10 years
AI integrated programs growing to 40% of Q2 FY2026 bookings is a real positive signal: pharma is paying MORE, not less, for AI-enhanced targeting — currently a tailwind not headwind
Scribe (3x user growth Q1-Q2) and Docs GPT create genuine workflow dependency that raises physician switching costs — but Microsoft/Nuance/Epic have better-positioned clinical workflow infrastructure
118% NRR is the strongest counter-argument to near-term disruption — current customers are expanding, not defecting to alternatives
Management explicitly acknowledges AI infrastructure cost ramp (back-half margin pressure) — honest about cost side, less forthcoming about demand-side displacement risk from pharma building own HCP data capabilities

Red flags

Pharma advertising is a matching intermediary revenue model — exactly the category most exposed to AI-enabled buyer self-sufficiency over a 5-10 year horizon
$31M settlement for alleged misstatement of user engagement/KPIs undermines confidence in the physician network engagement metrics that justify pharma willingness-to-pay
10-K risk factor language 43% above peer average on AI-related risks signals material internal uncertainty not fully reflected in bullish earnings call narrative
Microsoft/Nuance DAX embedded in Epic EHR represents a better-positioned incumbent for physician AI workflow — Doximity's standalone scribe/AI tools face commoditization from better-distributed competitors
Q3 guidance at only 7% growth implies meaningful deceleration — while partially attributable to timing shift, raises question whether pharma budgets are already rationalizing spend
Pathway acquisition is 6 people with no disclosed price — the AI clinical data strategy appears early-stage relative to what hyperscalers are deploying at scale

Howard Marks — 🟡 watch · 55/100 · medium confidence

DOCS sits in a genuinely interesting tension for a risk-first lens. The stock has declined ~75% from its 2021 highs and is now trading at $20.88 — near its 52-week low — with a DCF intrinsic value of $33.26 (base case) and a bear-case floor of $27.31. That is a 59% upside to base and 31% even to the bear case, which superficially looks like the kind of forced-selling/panic scenario I seek. However, I must separate the facts from the narrative: (1) The balance sheet is genuinely fortress-like — no debt, $65M cash, $979M stockholders' equity, current ratio of 6.6x, and zero capex. Permanent capital impairment risk from balance sheet fragility is essentially zero. (2) The business generates extraordinary FCF — $326M on $645M revenue (50.6% FCF margin), ROIC of 17%, and a 3-year revenue CAGR of 15.5%. This is not a distressed operating business. (3) The DCF uses 12% FCF growth and 10.7% WACC — these are reasonable but not conservative. The 71.9% terminal value dependency means the intrinsic value is highly sensitive to long-duration assumptions. At a more conservative 8% growth and 11% WACC, the intrinsic value compresses meaningfully. (4) The pricing in question: P/FCF of 11.7x and P/E of 19.5x are genuinely low for a 50%-FCF-margin SaaS business with 118% NRR and no debt. The PEG of 1.26 suggests fair-to-cheap. However, this is NOT a net-net, a credit situation, or a deeply distressed asset — it is a profitable growth software company that got de-rated from bubble-era highs. The crowd is not 'in love' with DOCS (sentiment is mixed-to-fearful, stock at all-time lows), which is a positive contrarian signal. (5) Second-level thinking test: The consensus view appears to be 'decent business, not exciting, macro uncertainty, growth slowing.' The risk is that Q3 guidance of only 7% growth and soft FY guidance mean 'the growth is gone.' My variant view: 118% NRR, 40% of bookings now AI-integrated, and a management team actively managing costs suggest the deceleration is partly structural/timing, not permanent impairment. But I cannot fully corroborate this from the filings excerpts alone. (6) Red flags I cannot dismiss: The $31M securities settlement alleging misstatement of KPIs (engagement metrics) creates real credibility risk — management may have been playing games with reported metrics in 2021-2023. Risk-factor language is 43% above peer average. AI margin pressure is real (EBITDA margins expected to compress from 60% to 55%+). Customer concentration (84% revenue from 121 customers) means a few losses could be material. (7) Sentiment: Fearful but not in full capitulation. Retail is asking 'am I an idiot?' — that's a mild positive contrarian signal but not the revulsion/forced-selling that marks a true bottom. The stock is at its all-time low, which is the kind of thing I pay attention to, but the 52-week data showing high=low=$20.88 suggests a data artifact in the price feed (the low_52w is listed as $17.15 but pct_below_52w_high is 0.0%), creating data uncertainty. Net: The bargain is real but not overwhelming. The safety is real (balance sheet, FCF, NRR). The risk-to-intrinsic-value asymmetry is modestly favorable. But this is not a forced-sale, not a credit situation, not priced for catastrophe — it is a decelerated growth SaaS at fair-to-modestly-cheap multiples with credibility overhang. The bar to clear for a 'pass' is: price at a steep discount to conservatively estimated value with wide margin of safety. Here, even at conservative DCF assumptions, there is upside, but the terminal value dependency and uncertain AI cost trajectory make the bear case closer to current price than I'd like for a conviction buy.

Key points

Price $20.88 vs. DCF bear-case $27.31 / base $33.26 — 31–59% upside suggests genuine discount even on conservative assumptions
Fortress balance sheet: zero debt, $979M equity, 6.6x current ratio, $326M FCF — permanent capital loss risk from structure is minimal
FCF margin 50.6%, ROIC 17%, 118% NRR, and 92% gross margin are exceptional operational quality that floors downside
P/FCF of 11.7x and P/E of 19.5x are low relative to business quality — crowd is not euphoric, sentiment is fearful/mixed (contrarian positive)
Stock down ~75% from highs; near 52-week lows; mixed-to-cautious retail sentiment; no forced institutional buying visible — pendulum has swung toward fear
AI-integrated programs now 40% of bookings, scribe tripling — real product momentum, not just narrative
No debt means no refinancing risk, no covenant traps, no liquidity crises in a downturn — survives a bad scenario

Red flags

$31M securities settlement for alleged misstatement of KPIs (2021–2023) damages management credibility; prior metric manipulation risk colors all reported engagement data
Risk-factor language 43% above peer average per 10-K May 2026 — management signaling elevated uncertainty across AI, legal, regulatory, and operational dimensions
Terminal value represents 71.9% of DCF intrinsic value — intrinsic estimate is highly sensitive to long-duration assumptions and compresses sharply under stress
Q3 FY2026 guidance only 7% revenue growth vs. 23% in Q2 — deceleration is sharp and management attributes partly to 'timing' without quantifying; execution risk real
Customer concentration: 84% of revenue from 121 customers — loss of even a handful could be materially negative
AI infrastructure cost ramp expected H2 FY2026 — EBITDA margin compression from 60% toward 55% is directionally unfavorable even if still high absolutely
Implied Q4 growth below historical norms — management's 'measured approach to unbooked revenue' signals genuine uncertainty, not just conservatism

Ray Dalio — 🟡 watch · 52/100 · medium confidence

Doximity is a macro-light, balance-sheet-pristine SaaS compounder — the kind of business where Dalio's regime-stress lens is only partially relevant but not irrelevant. The core tension: DOCS has an extraordinarily clean balance sheet (zero net debt, $64.8M cash, essentially no financial leverage, no floating-rate debt exposure), strong FCF generation ($326M, 50.6% margin), and a physician network with genuinely non-discretionary utility. These are Dalio-positive attributes. However, the revenue base is almost entirely pharma advertising/marketing spend — a discretionary, pro-cyclical budget line that gets cut early in downturns and is highly correlated to pharma sector health, capital markets sentiment, and (critically) the D2C regulatory environment. In a stagflationary or deflationary deleveraging scenario, pharma promotional budgets would face pressure even as the underlying drug products remain essential. DOCS passes the balance-sheet resilience test decisively but fails the regime-robustness test because it is a single-regime winner (expanding pharma budgets in a benign macro). The 84% revenue concentration in 121 large customers and near-100% US revenue further concentrate macro risk. The DCF intrinsic value of $33.26 vs. $20.88 current price (59% upside) provides some cushion, but the 71.9% terminal-value dependence means the valuation itself assumes the current growth regime persists — a classic Dalio red flag. AI cost inflation absorbing margins (management guiding from 60% to 55%+ EBITDA) adds a mild inflation-input risk. The $31M litigation settlement and 43%-above-peer risk-factor language signal governance/opacity risks that complicate stress-scenario modeling.

Key points

Zero net debt, $64.8M cash, no maturity wall, no floating-rate debt — balance sheet is highly resilient to a credit contraction or higher-for-longer rate regime; passes Dalio's debt-cycle stress test cleanly
FCF margin of 50.6% ($326M) and self-funding operations mean DOCS requires no capital market access even in a prolonged downturn — a rare and genuine Dalio strength
118% NRR and 84% revenue from 121 large pharma/health system customers creates customer stickiness but also concentration; non-discretionary physician workflow tools provide partial regime insulation
Revenue is overwhelmingly US-denominated pharma advertising spend — a pro-cyclical, single-geography revenue stream with no real FX diversification and meaningful correlation to pharma sector capex cycles
DCF intrinsic value $33.26 (base) with 71.9% terminal-value dependence implies valuation requires sustained 12% FCF growth and 2.5% terminal growth — vulnerable to regime shift that compresses multiples or slows pharma spend
AI infrastructure investment creating margin headwinds (60% to 55%+ EBITDA guided) suggests input-cost inflation is absorbing some FCF — modest but real Dalio flag on cost-pass-through
No inflation escalators in contracts visible from filings; pharma clients can delay or reduce promotional spend discretionarily, unlike essential inputs — weak pricing power in downturn
Policy uncertainty flagged by management (Trump admin D2C warnings, budget uncertainty) is a macro/regulatory regime risk with unquantified downside — DOCS single-regime dependence on permissive pharma marketing environment

Red flags

Single-regime dependence: revenue is pharma promotional spend, which is discretionary and would contract materially in a deflationary bust or stagflationary environment where pharma companies cut marketing budgets
100% US revenue — zero geographic diversification; full exposure to US policy, regulatory, and macro regime; Dalio's world-order framework penalizes this concentration
Valuation assumes persistent low-inflation, moderate-growth regime: 71.9% of DCF value sits in terminal value, predicated on uninterrupted 12% FCF growth and 2.5% perpetuity growth — zero cushion for regime shift
$31M litigation settlement and 43%-above-peer risk-factor language (per 10-K filing discussion) signal governance opacity and potential for additional tail liabilities not fully visible in balance sheet
High beta (1.28) confirms high correlation to broad equity market — adds beta, not diversification; portfolio diversification value is low relative to Dalio's 'uncorrelated return streams' standard
AI cost ramp (management guiding margin compression) with no quantified revenue offset yet — if AI investment doesn't monetize, FCF growth assumptions underpinning the DCF erode without a clear catalyst

Benjamin Graham — 🟡 watch · 52/100 · medium confidence

Doximity presents a genuinely mixed picture through the Graham lens. On the asset-light SaaS side, the company is deeply profitable, cash-generative, and carries essentially no debt — all admirable. However, several of Graham's core quantitative criteria are not met, preventing a confident 'pass.' The trailing P/E of ~19.5x exceeds Graham's defensive cap of 15x, though the earnings yield of 5.73% does compare favorably to current high-grade bond yields. The P/B of 3.9x combined with P/E of 19.5x gives a P/E × P/B product of roughly 75.9, well above Graham's 22.5 rule of thumb. There is no dividend record — Doximity pays no dividend, which Graham viewed as a meaningful discipline signal. The DCF intrinsic value of $33.26/share vs. a current price of $20.88 implies ~59% upside, and even the bear case of $27.31 is above the current price, suggesting the market is offering some discount — but the DCF relies heavily on terminal value (71.9% of enterprise value), which Graham would distrust as speculative. On the positive side: the balance sheet is fortress-like (current ratio 6.6x, debt-to-equity essentially zero, stockholders' equity $979M vs. total liabilities of only $178M), earnings have been consistently positive across all reported years (2021–2025), revenue CAGR of ~15.5% over 3 years, FCF margin expanding to 50.6%, and no losses in the look-back period. The net-net test clearly fails — current assets of $993M vs. total liabilities of $178M gives net current asset value of ~$815M, or roughly $4.46/share, nowhere near the $20.88 price. The price-to-FCF of 11.7x is the most compelling Grahamian metric — below 15x and suggesting real earnings power. The litigation settlement ($31M for alleged KPI misrepresentation) and elevated risk-factor language (43% above peer average) introduce credibility concerns Graham would weigh heavily. Soft guidance, AI margin pressure, and customer concentration (84% of revenue from 121 clients) add uncertainty to the earnings stability outlook. Overall: the business quality is higher than what Graham typically hunted, but the price is not cheap enough on earnings/book to clear his bar, and the absence of dividends and high P/E×P/B product keep this in 'watch' territory rather than a confident buy.

Key points

Trailing P/E of 19.5x exceeds Graham's 15x defensive ceiling, but price-to-FCF of 11.7x is more attractive and below threshold
Balance sheet is exceptionally strong: current ratio 6.6x, zero long-term debt, total liabilities only $178M vs. current assets of $993M
Earnings consistently positive across all 5 reported fiscal years (2021–2025), satisfying the earnings stability criterion
P/E × P/B product of ~75.9 far exceeds Graham's 22.5 rule, flagging overvaluation on combined basis
DCF intrinsic value $33.26 (bear $27.31, bull $38.06) vs. $20.88 price implies meaningful discount — but 71.9% of EV in terminal value makes this speculative by Graham standards
Net-net value ~$4.46/share; classic net-net test not even remotely met
No dividend history — fails Graham's dividend reliability criterion completely
FCF margin 50.6% and operating margin 33.3% demonstrate genuine, repeatable earnings power

Red flags

P/E × P/B product of ~75.9 far exceeds Graham's 22.5 threshold — combined multiple test fails materially
No dividend ever paid; Graham viewed dividend discipline as critical signal of financial stewardship
$31M litigation settlement for alleged misrepresentation of user engagement/KPIs raises credibility concerns about reported metrics
Risk-factor language in 10-K is 43% above peer average, signaling elevated disclosure uncertainty
Customer concentration: 84% of revenue from 121 clients — loss of a handful would be material and destabilizing
DCF heavily terminal-value dependent (71.9%) — Graham would dismiss this as speculative, not conservative intrinsic value
Soft forward guidance (Q3 only 7% growth), AI margin compression flagged by management, and policy uncertainty reduce near-term earnings visibility
Stock down ~75% from highs — prior valuation was clearly speculative, raising question of whether current price reflects genuine value or continued sentiment overhang

Seth Klarman — 🟡 watch · 52/100 · medium confidence

Doximity presents an interesting but imperfect case for value investing. The DCF intrinsic value of $33.26/share implies ~59% upside from the current $20.88 price, and the bear-case of $27.31 still represents 31% upside — suggesting some genuine margin of safety. However, Klarman-style value investing requires stress-testing that conservative estimate vigorously, and several concerns temper conviction. On the positive side: the balance sheet is fortress-like (current ratio 6.6x, debt-to-equity essentially zero, $64.8M cash plus ~$929M in total current assets vs. $149.8M current liabilities, with ~$979M stockholders' equity), FCF margins are exceptional at 50.6% ($326M on $645M revenue), and the business generates real, auditable cash. The P/FCF of 11.7x is genuinely low for a business of this quality. However, several Klarman-critical concerns apply: (1) The DCF is growth-dependent — it uses 12% FCF growth and 2.5% terminal growth; if growth decelerates materially (Q3 guidance implies only 7% revenue growth), the intrinsic value compresses significantly. A zero-growth perpetuity on current FCF at 10.7% WACC yields roughly $3B enterprise value or ~$16-17/share — below current price — meaning the margin of safety evaporates under stress. (2) The business is an intangible-asset platform; liquidation value is minimal and there is no hard asset floor. Net tangible assets backing is modest relative to market cap. (3) Revenue concentration (84% from 121 customers) creates binary risk from client loss. (4) The $31M securities litigation settlement (alleged KPI misstatement 2021-2023) raises governance/credibility concerns — exactly the kind of disclosure and management alignment red flag Klarman penalizes. (5) Risk-factor language in the 10-K is 43% above peer average — an automated signal of mounting legal, AI, and regulatory exposure. (6) No structural catalyst exists: this is not a spin-off, distressed situation, forced selling by an institution, or special situation with a specific value-unlocking event. The stock is cheap partly because growth decelerated and guidance softened — not because of indiscriminate selling that creates a temporary dislocation. (7) AI margin investment headwinds could compress the already-thin margin of safety further. The price-to-sales of 5.9x and P/E of 19.5x are not screaming-cheap on an absolute basis for a decelerating grower. The position is a 'watch' rather than 'pass' because the FCF yield (8.6% at current price), near-zero debt, and real cash generation prevent this from being a clear avoid — but it does not meet the Klarman bar of a wide, durable margin of safety grounded in downside-protected asset coverage or a specific catalyst.

Key points

FCF yield of ~8.6% at current price ($326M FCF / $3.82B market cap) is attractive in absolute terms
Balance sheet is genuinely strong: ~6.6x current ratio, no meaningful debt, ~$979M equity vs $177M liabilities
Bear-case DCF of $27.31 implies ~31% upside even under stress assumptions — provides some downside cushion
P/FCF of 11.7x is low for a 50%+ FCF-margin business, suggesting real cheapness on cash earnings
118% net revenue retention and 92% gross margins confirm durable, sticky revenue quality
Revenue CAGR of 15.5% over 3 years with consistent FCF generation reduces earnings quality risk

Red flags

Zero-growth stress test (FCF / WACC) implies intrinsic value near or below current price — margin of safety is growth-dependent, not asset-backed
No hard catalyst: this is not a special situation (spin-off, distress, forced seller) — value gap may persist indefinitely with no unlocking event
$31M securities litigation settlement for alleged KPI misstatement (2021-2023) raises management credibility and disclosure quality concerns
Risk-factor word count 43% above peer average signals elevated legal, AI-regulatory, and operational risk exposure per 10-K filing
Revenue concentration: 84% from 121 customers — losing even a handful of top clients creates material downside that could impair FCF thesis
Q3 FY2026 guidance of only 7% growth contradicts the 12% FCF growth assumption embedded in the base DCF, threatening intrinsic value estimate
AI infrastructure cost ramp (back-half FY2026) likely to compress margins below current 50%+ FCF levels, further eroding the valuation cushion
Platform business with minimal tangible asset backing — liquidation value provides no downside floor; the margin of safety rests entirely on going-concern FCF

Stanley Druckenmiller — 🔴 avoid · 32/100 · high confidence

DOCS is a high-quality business but fails the Druckenmiller framework on the criteria that matter most: the tape is in freefall (down 75% from highs, at all-time lows at $20.88), fundamentals are decelerating (Q3 guidance of only 7% YoY growth vs. 23% in Q2), earnings revisions are flat-to-negative after a May 2026 miss, and there is no identifiable near-term catalyst that the market hasn't already punished. The second derivative is clearly negative. Management itself is signaling caution with 'measured approach' language and flagging AI cost headwinds compressing margins from 60% to a targeted 55%+. The price action confirms the story is broken: stocks don't fall 75% from highs and sit at all-time lows while the thesis is inflecting positively. There is no defined invalidation point that a macro trader can use to size a position with discipline. The $31M securities fraud settlement and 10-K risk language 43% above peer average add reputational and legal noise that clouds earnings trajectory visibility. The DCF suggests ~59% upside to $33.26 intrinsic value, but this is a static valuation exercise, not a forward momentum signal — exactly the 'backward-looking cheap trap' I avoid. JPMorgan's Neutral at $26 reflects the Street's own uncertainty. The only thing working is FCF margin (50.6%) and NRR (118%), but both are lagging indicators. Until the tape reverses decisively, estimate revisions turn positive, and Q3/Q4 growth re-accelerates, this is a falling knife with no asymmetric entry setup for a concentrated bet.

Key points

Price at all-time lows ($20.88), down 75% from highs — tape is in confirmed downtrend, never fight the tape
Second derivative is negative: Q3 FY2026 guidance only 7% YoY growth vs 23% in Q2; deceleration is accelerating
Management flagging margin compression from AI infrastructure costs, moving from 60% to 55%+ EBITDA target
No identifiable catalyst in the next 12-18 months that the market has not already fully discounted and punished
DCF shows $33 intrinsic value but this is a static exercise; forward earnings direction is deteriorating not inflecting
NRR of 118% and FCF margin of 50.6% are quality indicators but lagging — they reflect past, not forward trajectory

Red flags

All-time low price action is the strongest possible 'tape disagrees with story' signal — a primary disqualifier
Q3 guidance of 7% growth represents severe deceleration; negative second derivative on revenue momentum
$31M securities fraud settlement signals prior credibility issues and creates ongoing legal/reputational overhang
10-K risk factor language 43% above peer average signals management is flagging elevated uncertainty internally
AI cost ramp will compress margins in back half FY2026 — forward earnings estimates face downward pressure
Customer concentration (84% revenue from 121 customers) means any budget reallocation creates binary outcomes
No clear invalidation point or catalyst timing edge — thesis is 'it's cheap and will recover' not a macro-driven setup
Policy uncertainty around pharma D2C budgets (Trump admin warning letters) adds unquantifiable macro headwind

Walter Schloss — 🔴 avoid · 28/100 · high confidence

Doximity is a capital-light software business whose value resides almost entirely in intangibles — its physician network, brand, and AI platform — rather than in tangible book value. From a Schloss perspective, the numbers are straightforwardly unfavorable. Price-to-book is 3.9x, which already tells most of the story, but the balance sheet reveals this is even worse than it appears on a tangible basis: total assets of $1.16B include substantial intangibles/goodwill (current assets alone are $993M, mostly cash/investments, leaving very little in the way of hard plant or inventory), and stockholders' equity of $979M is overwhelmingly composed of soft assets and retained earnings from a business that generates no capex (reported $0). There are no factory walls, no real estate, no machinery to anchor a downside appraisal. The stock is trading at $20.88 with a P/B of 3.9x — meaning you are paying nearly four times what the books say the assets are worth, and those 'assets' are largely cash plus intangible network value. This is not a Schloss bargain. Schloss bought businesses at or below book, ideally at a discount to net tangible assets, with hard assets providing a floor. Here there is essentially no tangible floor. The 52-week range is listed as $17.15 low to $76.51 high (52w high shown as $20.88 in price block which appears to be a data artifact — the fundamentals block lists the 52-week high at $76.51, confirming the stock is dramatically below its historical peak). While beaten-down prices attract Schloss attention, price decline alone is not sufficient — the asset backing must provide the margin of safety. At P/B 3.9x and price-to-FCF of 11.7x, the stock is cheap relative to earnings power and DCF intrinsic value ($33.26), but Schloss did not buy earnings power — he bought assets. The debt situation is actually favorable (debt-to-equity is null/essentially zero, current ratio 6.6x), which is a genuine positive. But the business is fundamentally asset-light software, heavily dependent on an earnings/growth narrative that Schloss would distrust. The litigation settlement ($31M, alleging misleading KPIs) adds a governance red flag. Insider activity shows RSU grants to CFO and President but no disclosed open-market purchases, and the company's value depends on intangible network effects that cannot be appraised from a balance sheet. This is precisely the type of name Schloss would decline to analyze deeply — not because it is a bad business, but because it does not fit his framework.

Key points

Price-to-book of 3.9x — far above Schloss's preferred near-or-below tangible book threshold
Balance sheet is mostly cash/investments and intangibles; essentially zero hard tangible assets (plant, equipment) to anchor downside appraisal
No long-term debt and current ratio of 6.6x are genuine positives for balance sheet strength
Stock is dramatically below 52-week high of $76.51 (beaten-down price is a Schloss prerequisite but insufficient alone)
Business value derives from physician network and AI platform — intangibles Schloss could not independently verify or appraise
FCF margin of 50% and operating margin of 33% confirm earnings quality, but Schloss anchors to assets, not earnings
DCF shows 59% upside to $33.26, but Schloss distrusted DCF and growth-narrative valuations

Red flags

Price-to-book 3.9x — pays 3.9x for every dollar of book, with no tangible asset floor
Asset-light SaaS model: value entirely in network effect and AI platform intangibles, not verifiable hard assets
$31M litigation settlement for alleged misrepresentation of user engagement KPIs — governance concern
Risk-factor language 43% above peer average per 10-K; management turnover flagged; AI regulatory exposure
No insider open-market buying disclosed; RSU grants to new CFO/President are compensation, not alignment signal
Thesis depends on continued AI monetization and pharma advertising spend — exactly the earnings/narrative dependency Schloss avoided
Margin pressure from AI infrastructure investment flagged by management — forward earnings uncertain

Fact base appendix

Price

last_close: 20.88
as_of: 2026-06-28
high_52w: 20.88
low_52w: 20.88
pct_below_52w_high: 0.0

Fundamentals

last_price: 20.88
market_cap: 3818368359
fifty_two_week_high: 76.51
fifty_two_week_low: 17.15
beta: 1.2797041
currency: USD
exchange: NEW YORK STOCK EXCHANGE, INC.
sector: Health Care
industry: Health Care
price_source: finnhub
bars: 1
entity: Doximity, Inc.
fiscal_year: 2025
revenue: 644863000
revenue_period: 2026-03-31
net_income: 196051000
net_income_period: 2026-03-31
operating_income: 214920000
operating_income_period: 2026-03-31
operating_cash_flow: 326458000
operating_cash_flow_period: 2026-03-31
capex: 0
capex_period: 2026-03-31
total_assets: 1157026000
total_assets_period: 2025-12-31
total_liabilities: 177728000
total_liabilities_period: 2025-12-31
current_assets: 993453000
current_assets_period: 2025-12-31
current_liabilities: 149848000
current_liabilities_period: 2025-12-31
stockholders_equity: 979298000
stockholders_equity_period: 2025-12-31
cash_and_equivalents: 64838000
cash_and_equivalents_period: 2025-12-31
operating_margin: 0.3333
net_margin: 0.304
roe: 0.2002
debt_to_equity: None
current_ratio: 6.6297
roic: 0.1734
free_cash_flow: 326458000
fcf_margin: 0.5062
revenue_cagr: 0.1545
revenue_cagr_years: 3
fundamentals_source: edgar_companyfacts
pe_ratio: 19.48
price_to_fcf: 11.7
price_to_sales: 5.92
price_to_book: 3.9
earnings_yield: 0.0573
peg: 1.26

Filings reviewed

10-K (2026-05-19) https://www.sec.gov/Archives/edgar/data/1516513/000151651326000025/docs-20260331.htm
8-K (2026-05-13) https://www.sec.gov/Archives/edgar/data/1516513/000151651326000017/docs-20260513.htm
8-K (2026-04-17) https://www.sec.gov/Archives/edgar/data/1516513/000151651326000014/docs-20260413.htm
10-Q (2026-02-05) https://www.sec.gov/Archives/edgar/data/1516513/000151651326000006/docs-20251231.htm
10-Q (2025-11-06) https://www.sec.gov/Archives/edgar/data/1516513/000151651325000111/docs-20250930.htm
10-K (2025-05-20) https://www.sec.gov/Archives/edgar/data/1516513/000151651325000056/docs-20250331.htm

Other sources

[news] Doximity Stock is Down 75% From Its Highs. Do Analysts See Recovery? - TIKR.com
[news] JPMorgan reiterates Doximity stock Neutral rating with $26 target - Investing.com
[news] Doximity (DOCS) CFO discloses 501,549 shares, including 499,722 RSUs, on Form 3 - Stock Titan
[news] Doximity (DOCS) President Steven Zatz receives 55,524 restricted stock units - Stock Titan
[news] Doximity (NYSE: DOCS) president discloses 822 Class A shares - Stock Titan
[news] Doximity Stock Falls on Q4 Earnings Miss, Revenues Beat, Margins Down - Yahoo Finance
[news] Doximity shares hit record low as soft guidance and AI margin pressures spark 25% plunge (DOCS:NYSE) - Seeking Alpha
[news] Is Doximity, Inc. (DOCS) A Good Stock To Buy Now? - Yahoo Finance
[news] Price to earnings forward of Doximity, Inc. – BOATS:DOCS - TradingView
[news] Doximity, Inc. (DOCS) Stock Report: Analyst Ratings Point To A Promising 26% Upside - DirectorsTalk Interviews
[news] Doximity Inc. (NYSE:DOCS): A GARP Stock With Strong Growth and a Reasonable Price - ChartMill
[news] Doximity, Inc. Class A Actuals & Estimates (NYSE:DOCS) - TradingView
[news] Doximity Inc (DOCS) Shares Fall 4.7% -- What GF Score of 82 Tells Investors - GuruFocus
[news] Doximity: Cheaper, But Growth Is Still Missing (NYSE:DOCS) - Seeking Alpha
[news] Doximity (DOCS) Up 11.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
[discussion] $DOCS If you bought $DOCS there's still time to file a claim before the settlement deadline on
[discussion] Reminder: $DOCS $31M investor settlement deadline is July 16, 2026.

Investors who bought betwee

[discussion] $DOCS Outstanding article that hits the mark on DOCS's current state. So if you want to refresh
[discussion] $DOCS Share Price: $20.69

Contract Selected: Nov 20, 2026 $20 Calls

Buy Zone: $3.65 – $4.51 Target

[discussion] $DOCS - Deadline reminder for Doximity investors.

A $31 million settlement is currently accepting

[discussion] $TEM $DOCS $CRSP bought these
[discussion] $DOCS investors — there’s no hidden secret here. Just one thing you really need to know. Here’s ho
[discussion] $DOCS - Doximity Inc - 10K - Updated Risk Factors

🚨 Peer Alert: Risk-factor words are +43.1% abov

[discussion] $DOCS i bought this today ....can someone please tell me that im not a idiot for buying this ?....
[discussion] https://www.marketbeat.com/earnings/reports/2026-5-19-dr-martens-plc-stock-1/

$DOCS Dr. Martens Ear

[discussion] https://marketbeat.com/a/8662620/

$DOCS

Dr. Martens H2 Earnings Call Highlights

[discussion] [Bullish] $DOCS
[discussion] [Bullish] $DOCS
[discussion] [Bullish] $DOCS
[discussion] $DOCS pump it to 25 so that we can again short it to 15 this time lol
[earnings_call] Doximity, Inc DOCS Q2 2026 Earnings Call

Generated 2026-07-17T19:47:33 · est. cost $1.46

What each investor thinks

Terry Smith (Fundsmith) Quality

pass · 76

Valuation Referee (Damodaran-style) Referee

pass · 74

Charlie Munger Quality

pass · 74

Michael Mauboussin Quality

pass · 74

Forensic Short-Seller (Chanos/Einhorn-style) Referee

pass · 72

Chuck Akre Quality

watch · 62

Warren Buffett Quality

watch · 62

Philip Fisher Growth

watch · 62

Joel Greenblatt Value

watch · 58

Bruce Greenwald Value

watch · 58

Peter Lynch Growth

watch · 58

AI & Disruption Referee (Christensen-style) Referee

watch · 58

Howard Marks Risk

watch · 55

Ray Dalio Risk

watch · 52

Benjamin Graham Value

watch · 52

Seth Klarman Value

watch · 52

Stanley Druckenmiller Risk

avoid · 32

Walter Schloss Value

avoid · 28

Want this on a name you own?Send a ticker; we convene the full council on it.

Request Analysis →